This site uses cookies to improve your browsing experience. By continuing to browse this site you are agreeing to our use of cookies. For further information, please refer to Privacy Policy.
Shine-On BioMedical
  • LANGUAGE
    • 繁體中文
    • English
  • ABOUT
    • Overview
    • Milestone
    • Mission
    • Organization
    • Management and consulting team
  • Core Technologies
    • Targeted exosome for drug delivery
    • Trispecific T cell engager antibody
  • R&D Pipeline
    • Targeted exosome for drug delivery
      • SOB100: HLA-G targeted exosome (αHLA-G exo)
      • SOB101: HLA-G targeted exosomal doxorubicin
      • SOB102: HLA-G targeted exosomal microRNA
      • SOB201: Genetically engineered stem cell-derived exosomes
    • Trispecific T cell engager antibody
      • SOA101: Nanobody-based trispecific antibody T cell engager (Nb-TriTE)
      • SOA201: EphA10-trispecific immune cell engager antibody
    • Exosome-derived products
      • SOC101&SOC102
    • Products Pipeline
  • News
  • Links
    • 政府機構
    • 學術機構
    • 產業新知
  • Investor Zone
  • Sustainable development CSR
    • Sustainable development CSR
    • Ethics compliance and whistleblower protection
  • Stakeholders Area
  • Contact
  • Disclaimer
  • Terms
  • Privacy

News

  1. HOME
  2. News
  • 23MAR

    The Ministry of Health and Welfare conti...

    The Ministry of Health and Welfare continues to promote the "three methods of regenerative medicine" and expands organelles, seeking review by the Executive Yuan in Q2
  • 07FEB

    Latest U.S. FDA regulations: human gene ...

    Latest U.S. FDA regulations: human gene therapy to treat rare diseases
  • 20DEC

    The latest U.S. FDA regulations: Chemica...

    The latest U.S. FDA regulations: Chemical manufacturing controls for human gene therapy new drug clinical trial applications

04-2327-2888

E-mail : service@shineon-bio.com

Rm. B, 10F., No. 573, Sec. 2, Taiwan Blvd., West Dist., Taichung City 403020, Taiwan

NAVIGATION
  • ABOUT
  • Core Technologies
  • R&D Pipeline
  • News
  • Links
  • Investor Zone
  • Sustainable development CSR
  • Stakeholders Area
  • Contact
  • Disclaimer
  • Terms
  • Privacy
  • HOME
Copyright © 2024 - Shine-On BioMedical Web design : Newscan
TOP
LANGUAGE
  • 繁體中文
  • English
  • ABOUT
    • Overview
    • Milestone
    • Mission
    • Organization
    • Management and consulting team
  • Core Technologies
    • Targeted exosome for drug delivery
    • Trispecific T cell engager antibody
  • R&D Pipeline
    • Targeted exosome for drug delivery
      • SOB100: HLA-G targeted exosome (αHLA-G exo)
      • SOB101: HLA-G targeted exosomal doxorubicin
      • SOB102: HLA-G targeted exosomal microRNA
      • SOB201: Genetically engineered stem cell-derived exosomes
    • Trispecific T cell engager antibody
      • SOA101: Nanobody-based trispecific antibody T cell engager (Nb-TriTE)
      • SOA201: EphA10-trispecific immune cell engager antibody
    • Exosome-derived products
      • SOC101&SOC102
    • Products Pipeline
  • News
  • Links
    • 政府機構
    • 學術機構
    • 產業新知
  • Investor Zone
  • Sustainable development CSR
    • Sustainable development CSR
    • Ethics compliance and whistleblower protection
  • Stakeholders Area
  • Contact
  • Disclaimer
  • Terms
  • Privacy